About Prana Biotechnology (NASDAQ:PRAN)
Prana Biotechnology Limited develops therapies for the treatment of Alzheimer's disease, Huntington disease, and other neurodegenerative disorders in Australia. Its lead drug candidates include PBT2, which is in Phase IIb clinical trials for the treatment of Alzheimer's: and that is in Phase IIa clinical trials for the treatment of Huntington's diseases. The company is also developing PBT434, which is in preclinical toxicology stage for the treatment for Parkinson's disease and other movement disorders; and PBT 519 that is in preclinical toxicology stage for the treatment of brain cancer. It also has a library of approximately 1000 metal protein attenuating compounds. The company has a research collaboration agreement with Takeda Pharmaceuticals International, Inc. to slow or prevent neurodegeneration of the gastrointestinal system through PBT434, an investigational movement disorders compound. Prana Biotechnology Limited was founded in 1997 and is based in Melbourne, Australia.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:PRAN
CUSIPN/A
Phone61-3-9349-4906
Debt
Debt-to-Equity RatioN/A
Current Ratio12.11%
Quick RatioN/A
Price-To-Earnings
Trailing P/E Ratio-3.08
Forward P/E Ratio-2.45
P/E GrowthN/A
Sales & Book Value
Annual Sales$100,000.00
Price / Sales174.44
Cash FlowN/A
Price / CashN/A
Book Value$2.01 per share
Price / Book0.98
Profitability
EPS (Most Recent Fiscal Year)N/A
Net IncomeN/A
Net MarginsN/A
Return on EquityN/A
Return on AssetsN/A
Miscellaneous
Employees9
Outstanding Shares8,900,000
Prana Biotechnology (NASDAQ:PRAN) Frequently Asked Questions
What is Prana Biotechnology's stock symbol?
Prana Biotechnology trades on the NASDAQ under the ticker symbol "PRAN."
What price target have analysts set for PRAN?
1 brokers have issued 12-month price objectives for Prana Biotechnology's shares. Their predictions range from $4.00 to $4.00. On average, they anticipate Prana Biotechnology's stock price to reach $4.00 in the next twelve months. View Analyst Ratings for Prana Biotechnology.
Who are some of Prana Biotechnology's key competitors?
Some companies that are related to Prana Biotechnology include Neurotrope (NTRP), vTv Therapeutics (VTVT), Regulus Therapeutics (RGLS), Axsome Therapeutics (AXSM), Helix Biopharma (HBPCF), Vascular Biogenics (VBLT), Sophiris Bio (SPHS), Vernalis (VNLPY), Scynexis (SCYX), Acerus Pharmaceuti (TRLPF), Genprex (GNPX), Versartis (VSAR), Arcturus Therapeutics (ARCT), LifeVantage (LFVN) and Pain Therapeutics (PTIE).
Who are Prana Biotechnology's key executives?
Prana Biotechnology's management team includes the folowing people:
- Mr. Geoffrey Paul Kempler B.Sc, Grad.Dip.App.Soc.Psych, Co-Founder, Exec. Chairman, CEO & MD (Age 63)
- Ms. Kathryn Andrews B.Com, CPA, Chief Financial Officer (Age 51)
- Ms. Dianne M. Angus, Chief Operating Officer (Age 58)
- Dr. David A. Stamler M.D., Chief Medical Officer, Sr. VP of Clinical Devel. and Member of R&D Advisory Board (Age 57)
- Prof. Rudolph Emile Tanzi Ph.D., Chief Scientific Advisor and Member of R&D Advisory Board
Has Prana Biotechnology been receiving favorable news coverage?
News coverage about PRAN stock has trended somewhat positive this week, Accern Sentiment reports. Accern ranks the sentiment of news coverage by monitoring more than twenty million blog and news sources in real time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Prana Biotechnology earned a news sentiment score of 0.09 on Accern's scale. They also gave media coverage about the biotechnology company an impact score of 46.38 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the stock's share price in the next few days.
How do I buy shares of Prana Biotechnology?
Shares of PRAN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Prana Biotechnology's stock price today?
One share of PRAN stock can currently be purchased for approximately $1.96.
How big of a company is Prana Biotechnology?
Prana Biotechnology has a market capitalization of $17.44 million and generates $100,000.00 in revenue each year. The biotechnology company earns $-5,680,000.00 in net income (profit) each year or ($0.64) on an earnings per share basis. Prana Biotechnology employs 9 workers across the globe.
How can I contact Prana Biotechnology?
Prana Biotechnology's mailing address is LEVEL 2 369 ROYAL PARADE, PARKVILLE C3, 3052. The biotechnology company can be reached via phone at 61-3-9349-4906 or via email at [email protected]
MarketBeat Community Rating for Prana Biotechnology (PRAN)
MarketBeat's community ratings are surveys of what our community members think about Prana Biotechnology and other stocks. Vote "Outperform" if you believe PRAN will outperform the S&P 500 over the long term. Vote "Underperform" if you believe PRAN will underperform the S&P 500 over the long term. You may vote once every thirty days.
Prana Biotechnology (NASDAQ:PRAN) Price Target and Consensus Rating
(How are Consensus Ratings Calculated?) MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
1 Wall Street analysts have issued ratings and price targets for Prana Biotechnology in the last 12 months. Their average twelve-month price target is $4.00, suggesting that the stock has a possible upside of 104.08%. The high price target for PRAN is $4.00 and the low price target for PRAN is $4.00. There are currently 1 buy rating for the stock, resulting in a consensus rating of "Buy."
| Today | 30 Days Ago | 90 Days Ago | 180 Days Ago |
| Consensus Rating: | Buy | Buy | Buy | N/A |
| Consensus Rating Score: | 3.00 | 3.00 | 3.00 | N/A |
| Ratings Breakdown: | 0 Sell Rating(s)
0 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
0 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
0 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
0 Hold Rating(s)
0 Buy Rating(s)
0 Strong Buy Rating(s) |
| Consensus Price Target: | $4.00 | $4.00 | $4.00 | N/A |
| Price Target Upside: | 104.08% upside | 26.18% upside | 26.18% upside | N/A |
Prana Biotechnology (NASDAQ:PRAN) Consensus Price Target History
Prana Biotechnology (NASDAQ:PRAN) Analyst Ratings History
Show:
| Date | Brokerage | Action | Rating | Price Target | Impact on Share Price | Details |
|---|
| 1/5/2018 | B. Riley | Set Price Target | Buy -> Buy | $4.00 | Medium |  |
(Data available from 4/25/2016 forward)
Prana Biotechnology (NASDAQ:PRAN) Dividend History by Quarter
| Announced | Period | Amount | Yield | Ex-Dividend Date | Record Date | Payable Date |
|---|
(Data available from 1/1/2013 forward)
Prana Biotechnology (NASDAQ PRAN) Insider Trading and Institutional Ownership History
Insider Ownership Percentage: 38.80%
Institutional Ownership Percentage: 2.35%
Prana Biotechnology (NASDAQ PRAN) Insider Trading History
| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Shares Held After Transaction | Details |
|---|
(Data available from 1/1/2013 forward)
Prana Biotechnology (NASDAQ PRAN) News Headlines
| Source: |
|
Prana Biotechnology (NASDAQ:PRAN) SEC Filings
This page is loading this company's SEC Filings. Please wait...
Prana Biotechnology (NASDAQ:PRAN) Income Statement, Balance Sheet and Cash Flow Statement
Prana Biotechnology (NASDAQ PRAN) Stock Chart for Wednesday, April, 25, 2018
Loading chart…
